BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santiago-Sánchez GS, Noriega-Rivera R, Hernández-O'Farrill E, Valiyeva F, Quiñones-Diaz B, Villodre ES, Debeb BG, Rosado-Albacarys A, Vivas-Mejía PE. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. Int J Mol Sci 2021;22:8581. [PMID: 34445288 DOI: 10.3390/ijms22168581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Kuo C, Hsieh P, Chiu V, Lan C, Lu K. The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways. Oxidative Medicine and Cellular Longevity 2023;2023:1-15. [DOI: 10.1155/2023/7736638] [Reference Citation Analysis]
2 Mchenry PR, Prosperi JR. Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential. IJMS 2023;24:2100. [DOI: 10.3390/ijms24032100] [Reference Citation Analysis]
3 Wu Y, Li X, Li Q, Cheng C, Zheng L. Adipose tissue-to-breast cancer crosstalk: Comprehensive insights. Biochim Biophys Acta Rev Cancer 2022;1877:188800. [PMID: 36103907 DOI: 10.1016/j.bbcan.2022.188800] [Reference Citation Analysis]
4 Valashedi MR, Roushandeh AM, Tomita K, Kuwahara Y, Pourmohammadi-Bejarpasi Z, Kozani PS, Sato T, Roudkenar MH. CRISPR/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerability. Life Sci 2022;304:120704. [PMID: 35714703 DOI: 10.1016/j.lfs.2022.120704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Crescenzi E, Leonardi A, Pacifico F. NGAL as a Potential Target in Tumor Microenvironment. Int J Mol Sci 2021;22:12333. [PMID: 34830212 DOI: 10.3390/ijms222212333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]